3. 1) Cipro (Ciprofloxacin)
Dosage (adult)
Acute complicated UTI: 250mg q12h for 3days
LRTI: Mild/moderate: 500mg q12h for 10days.
Severe/Complicated: 750mg q12h for 4-6 weeks
Acute sinusitis: Mild/moderate: 500mg q12h for
10days
4. 1) Cipro (Ciprofloxacin)
Warnings (Boxed Warning)
“Fluoroquinolones are associated with an increased
risk of tendinitis and tendon rupture in all ages.
Risk is further increased in patients >60 yrs”
D/C if experience pain, swelling, inflammation or
rupture of tendon.
6. 1) Cipro (Ciprofloxacin)
Mechanism of Action
inhibits
enzymes topoisomerase II (DNA gyrase)
and topoisomerase IV (both Type II
topoisomerases), which are required for bacterial
DNA replication, transcription, repair, and
recombination.
7. 2) Ventolin HFA (albuterol sulfate)
Indications
Treatment or prevention of bronchospasm with
reversible obstructive airway disease and
prevention of exercise-induced bronchospasm
(EIB) in patients ≥4 yrs.
8. 2) Ventolin HFA (albuterol sulfate)
Dosage (adults)
Treatment/Prevention of Bronchospasm: 2 inh q4-
6h or 1 inh q4h. EIB: 2 inh 15-30 min before
exercise. Elderly: Start at lower end of dosing
range.
Dosage (pediatrics)
≥4yrs: Treatment/Prevention of Bronchospasm: 2
inh q4-6h or 1 inh q4h. EIB: 2 inh 15-30 min
before exercise.
9. 2) Ventolin HFA (albuterol sulfate)
Warnings/Precautions
D/C if paradoxical bronchospasm or
cardiovascular (CV) effects occur. More doses
than usual may be a marker of destabilization of
asthma and may require reevaluation of the
patient and treatment regimen; give special
consideration to the possible need for anti-
inflammatory treatment (eg, corticosteroids).
11. 2) Ventolin HFA (albuterol sulfate)
Mechanism of Action
β2-agonist; activates β2-adrenergic receptors on
airway smooth muscle leading to the activation of
adenylcyclase and to an increase in the
intracellular cyclic-3',5'-adenosine
monophosphate (cAMP). Increased cAMP leads
to the activation of protein kinase A, which inhibits
the phosphorylation of myosin and lowers
intracellular ionic calcium concentrations,
resulting in relaxation of the smooth muscles of all
airways, from the trachea to the terminal
bronchioles.
12. 3) Flonase (fluticasone propionate)
Indications
Management of the nasal symptoms of seasonal
and perennial allergic and nonallergic rhinitis in
adults and pediatrics ≥4 yrs.
13. 3) Flonase (fluticasone propionate)
Dosage (adult)
Initial:2 sprays per nostril qd or 1 spray per nostril
bid. Maint: 1 spray per nostril qd. May dose as 2
sprays per nostril qd PRN for seasonal allergic
rhinitis.
Dosage (pediatric)
≥4 yrs: Initial: 1 spray per nostril qd. If inadequate
response, may increase to 2 sprays per nostril.
Maint: 1 spray per nostril qd. Max: 2 sprays per
nostril/day.
14. 3) Flonase (fluticasone propionate)
Warnings/Precautions
Caution with active or quiescent tuberculosis
(TB), ocular herpes simplex, or untreated
bacterial, fungal, and systemic viral or parasitic
infections. Avoid with recent nasal trauma,
surgery, or septal ulcers. Risk for more
severe/fatal course of infections (eg, chickenpox,
measles); avoid exposure in patients who have
not had disease or not have been properly
immunized.
16. 3) Flonase (fluticasone propionate)
Mechanism of Action
Synthetic trifluorinated corticosteroid; not
established. Anti-inflammatory agent with wide
range of effects on multiple cell types (eg, mast
cells, eosinophils, macrophages, and
lymphocytes) and mediators (eg, histamine,
eicosanoids, leukotrienes, and cytokines)
involved in inflammation.
